Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian CancerHui Zhang, Karl R. Klauser, Tao Liu et al.|Cell|2016Cited by 1.1k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trialCaicun Zhou, Jianjun Zou, Gongyan Chen et al.|The Lancet Respiratory Medicine|2020Cited by 504
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trialJianxing He, Caicun Zhou, Chunxia Su et al.|The Lancet Respiratory Medicine|2021Cited by 183
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Gustavo Werutsky et al.|Journal of Clinical Oncology|2024Cited by 137
Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trialTao Jiang, Shengxiang Ren, Pingyang Wang et al.|Signal Transduction and Targeted Therapy|2021Cited by 94